Literature DB >> 29497862

Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.

Kelly C Gast1, Paul V Viscuse1, Somaira Nowsheen2, Tufia C Haddad3, Robert W Mutter4, Andrea E Wahner Hendrickson3, Fergus J Couch5, Kathryn J Ruddy6.   

Abstract

PURPOSE OF REVIEW: BRCA1 and BRCA2 mutation carriers can be at increased cardiovascular risk. The goal of this review is to provide information about factors associated with increased cardiovascular risk, methods to prevent cardiovascular toxicities, and recommended screening guidelines. RECENT
FINDINGS: BRCA1/2 mutation carriers who are diagnosed with cancer are often exposed to chemotherapy, chest radiotherapy, and/or HER2 directed therapies, all of which can be cardiotoxic. In addition, BRCA1/2 carriers often undergo prophylactic salpingoopherectomies, which may also increase cardiovascular risks. Understanding the potential for increased cardiovascular risk in individuals with a BRCA1 or BRCA2 mutation, as well as gold standard practices for prevention, detection, and treatment of cardiac concerns in this population, is important.

Entities:  

Keywords:  BRCA mutation; Cardio-oncology; Chemotherapy cardiotoxicity; Radiation cardiotoxicity

Year:  2018        PMID: 29497862     DOI: 10.1007/s11936-018-0609-z

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  127 in total

Review 1.  Nutrition and physical activity guidelines for cancer survivors.

Authors:  Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler
Journal:  CA Cancer J Clin       Date:  2012-04-26       Impact factor: 508.702

Review 2.  Advances in radiotherapy.

Authors:  Saif S Ahmad; Simon Duke; Rajesh Jena; Michael V Williams; Neil G Burnet
Journal:  BMJ       Date:  2012-12-04

3.  Cardiac arrest and ventricular fibrillation in a young man treated with capecitabine: Case report and literature review.

Authors:  Luisa De Gennaro; Natale Daniele Brunetti; Manuela Resta; David Rutigliano; Luigi Tarantini; Pasquale Caldarola
Journal:  Int J Cardiol       Date:  2016-06-23       Impact factor: 4.164

4.  Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

Authors:  Daniela Cardinale; Alessandro Colombo; Giulia Bacchiani; Ines Tedeschi; Carlo A Meroni; Fabrizio Veglia; Maurizio Civelli; Giuseppina Lamantia; Nicola Colombo; Giuseppe Curigliano; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2015-05-06       Impact factor: 29.690

Review 5.  PARP inhibitors: Synthetic lethality in the clinic.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Science       Date:  2017-03-16       Impact factor: 47.728

6.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.

Authors:  L C Hartmann; D J Schaid; J E Woods; T P Crotty; J L Myers; P G Arnold; P M Petty; T A Sellers; J L Johnson; S K McDonnell; M H Frost; R B Jenkins
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

7.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Authors:  Timothy R Rebbeck; Tara Friebel; Henry T Lynch; Susan L Neuhausen; Laura van 't Veer; Judy E Garber; Gareth R Evans; Steven A Narod; Claudine Isaacs; Ellen Matloff; Mary B Daly; Olufunmilayo I Olopade; Barbara L Weber
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

8.  Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.

Authors:  Marline G Harmsen; Marieke Arts-de Jong; Nicoline Hoogerbrugge; Angela H E M Maas; Judith B Prins; Johan Bulten; Steven Teerenstra; Eddy M M Adang; Jurgen M J Piek; Helena C van Doorn; Marc van Beurden; Marian J E Mourits; Ronald P Zweemer; Katja N Gaarenstroom; Brigitte F M Slangen; M Caroline Vos; Luc R C W van Lonkhuijzen; Leon F A G Massuger; Rosella P M G Hermens; Joanne A de Hullu
Journal:  BMC Cancer       Date:  2015-08-19       Impact factor: 4.430

9.  The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers.

Authors:  Helen Cavanagh; Katherine M A Rogers
Journal:  Hered Cancer Clin Pract       Date:  2015-08-01       Impact factor: 2.857

Review 10.  PARP inhibitors in the management of breast cancer: current data and future prospects.

Authors:  Luca Livraghi; Judy E Garber
Journal:  BMC Med       Date:  2015-08-13       Impact factor: 8.775

View more
  3 in total

1.  Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists.

Authors:  Angela H E M Maas; Giuseppe Rosano; Renata Cifkova; Alaide Chieffo; Dorenda van Dijken; Haitham Hamoda; Vijay Kunadian; Ellen Laan; Irene Lambrinoudaki; Kate Maclaran; Nick Panay; John C Stevenson; Mick van Trotsenburg; Peter Collins
Journal:  Eur Heart J       Date:  2021-03-07       Impact factor: 29.983

2.  Vascular endothelium function among male carriers of BRCA 1&2 germline mutation.

Authors:  Guy Witberg; Eli Lev; Yaara Ber; Tzlil Tabachnik; Sivan Sela; Ira Belo; Dorit Leshem-Lev; David Margel
Journal:  Oncotarget       Date:  2019-08-20

3.  Associations of Plasma Bioactive Adrenomedullin Levels with Cardiovascular Risk Factors in BRCA1/2 Mutation Carriers.

Authors:  Jacqueline Lammert; Maryam Basrai; Joachim Struck; Oliver Hartmann; Christoph Engel; Stephan C Bischoff; Anika Berling-Ernst; Martin Halle; Marion Kiechle; Sabine Grill
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-06-03       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.